Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathway

Biochemical and Biophysical Research Communications

Volumn 396, Issue 2, 2010, Pages 199-205

  Hou, Xinguo ^a,b,c   Song, Jun ^a,b,c   Li, Xiao Nan ^a,b,c   Zhang, Lin ^b,c   Wang, XingLi ^b,c   Chen, Li ^a   Shen, Ying H ^b,c  

^a SHANDONG UNIVERSITY   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c TEXAS HEART INSTITUTE   (United States)

Author keywords

AMP activated protein kinase; Forkhead transcription factor 3; Metformin; Reactive oxygen species; Thioredoxin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; PALMITIC ACID; REACTIVE OXYGEN METABOLITE; THIOREDOXIN; TRANSCRIPTION FACTOR FKHRL1;

ANTIOXIDANT ACTIVITY; AORTA; ARTICLE; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PALMITIC ACID; PROTEIN KINASES; REACTIVE OXYGEN SPECIES; THIOREDOXINS; UP-REGULATION;

EID: 77952741468     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.04.017     Document Type: Article

References (43)

1. Madamanchi N.R., and Runge M.S. Mitochondrial dysfunction in atherosclerosis. Circ. Res. 100 (2007) 460-473
2. Yamawaki H., Haendeler J., and Berk B.C. Thioredoxin: a key regulator of cardiovascular homeostasis. Circ. Res. 93 (2003) 1029-1033
3. Berndt C., Lillig C.H., and Holmgren A. Thiol-based mechanisms of the thioredoxin and glutaredoxin systems: implications for diseases in the cardiovascular system. Am. J. Physiol. Heart Circ. Physiol. 292 (2007) H1227-H1236
4. Samuel S.M., Thirunavukkarasu M., Penumathsa S.V., Koneru S., Zhan L., Maulik G., Sudhakaran P.R., and Maulik N. Thioredoxin-1 gene therapy enhances angiogenic signaling and reduces ventricular remodeling in infarcted myocardium of diabetic rats. Circulation 121 (2010) 1244-1255
5. Abbasi F., Chu J.W., McLaughlin T., Lamendola C., Leary E.T., and Reaven G.M. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism 53 (2004) 159-164
6. Bhalla R.C., Toth K.F., Tan E., Bhatty R.A., Mathias E., and Sharma R.V. Vascular effects of metformin. Possible mechanisms for its antihypertensive action in the spontaneously hypertensive rat. Am. J. Hypertens. 9 (1996) 570-576
7. Clarke P., Gray A., Adler A., Stevens R., Raikou M., Cull C., Stratton I., and Holman R. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia 44 (2001) 298-304
8. Bellin C., de Wiza D.H., Wiernsperger N.F., and Rosen P. Generation of reactive oxygen species by endothelial and smooth muscle cells: influence of hyperglycemia and metformin. Horm. Metab. Res. 38 (2006) 732-739
9. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M., Ventre J., Doebber T., Fujii N., Musi N., Hirshman M.F., Goodyear L.J., and Moller D.E. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108 (2001) 1167-1174
10. Zou M.H., Hou X.Y., Shi C.M., Nagata D., Walsh K., and Cohen R.A. Modulation by peroxynitrite of Akt- and AMP-activated kinase-dependent Ser1179 phosphorylation of endothelial nitric oxide synthase. J. Biol. Chem. 277 (2002) 32552-32557
11. Fisslthaler B., Fleming I., Keseru B., Walsh K., and Busse R. Fluid shear stress and NO decrease the activity of the hydroxy-methylglutaryl coenzyme A reductase in endothelial cells via the AMP-activated protein kinase and FoxO1. Circ. Res. 100 (2007) e12-e21
12. Guo D., Chien S., and Shyy J.Y. Regulation of endothelial cell cycle by laminar versus oscillatory flow: distinct modes of interactions of AMP-activated protein kinase and Akt pathways. Circ. Res. 100 (2007) 564-571
13. Gaskin F.S., Kamada K., Yusof M., and Korthuis R.J. 5′-AMP-activated protein kinase activation prevents postischemic leukocyte-endothelial cell adhesive interactions. Am. J. Physiol. Heart Circ. Physiol. 292 (2007) H326-H332
14. Ido Y., Carling D., and Ruderman N. Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. Diabetes 51 (2002) 159-167
15. Li X.N., Song J., Zhang L., Lemaire S.A., Hou X., Zhang C., Coselli J.S., Chen L., Wang X.L., Zhang Y., and Shen Y.H. Activation of the AMPK-FOXO3 pathway reduces fatty acid-induced increase in intracellular reactive oxygen species by upregulating thioredoxin. Diabetes 58 (2009) 2246-2257
16. Wang X.L., Zhang L., Youker K., Zhang M.X., Wang J., LeMaire S.A., Coselli J.S., and Shen Y.H. Free fatty acids inhibit insulin signaling-stimulated endothelial nitric oxide synthase activation through upregulating PTEN or inhibiting Akt kinase. Diabetes 55 (2006) 2301-2310
17. Li X., Rong Y., Zhang M., Wang X.L., LeMaire S.A., Coselli J.S., Zhang Y., and Shen Y.H. Up-regulation of thioredoxin interacting protein (Txnip) by p38 MAPK and FOXO1 contributes to the impaired thioredoxin activity and increased ROS in glucose-treated endothelial cells. Biochem. Biophys. Res. Commun. 381 (2009) 660-665
18. Shen Y.H., Zhang L., Gan Y., Wang X., Wang J., Lemaire S.A., Coselli J.S., and Wang X.L. Up-regulation of PTEN (phosphatase and tensin homolog deleted on chromosome ten) mediates p38 MAPK stress signal-induced inhibition of insulin signaling: a cross-talk between stress signaling and insulin signaling in resistin-treated human endothelial cells. J. Biol. Chem. 281 (2006) 7727-7736
19. Greer E.L., Oskoui P.R., Banko M.R., Maniar J.M., Gygi M.P., Gygi S.P., and Brunet A. The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. J. Biol. Chem. 282 (2007) 30107-30119
20. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group, Lancet 352 (1998) 837-853.
21. Bonnefont-Rousselot D., Raji B., Walrand S., Gardes-Albert M., Jore D., Legrand A., Peynet J., and Vasson M.P. An intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress. Metabolism 52 (2003) 586-589
22. Ouslimani N., Peynet J., Bonnefont-Rousselot D., Therond P., Legrand A., and Beaudeux J.L. Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells. Metabolism 54 (2005) 829-834
23. Li L., Mamputu J.C., Wiernsperger N., and Renier G. Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin. Diabetes 54 (2005) 2227-2234
24. Faure P., Rossini E., Wiernsperger N., Richard M.J., Favier A., and Halimi S. An insulin sensitizer improves the free radical defense system potential and insulin sensitivity in high fructose-fed rats. Diabetes 48 (1999) 353-357
25. Okuda M., Inoue N., Azumi H., Seno T., Sumi Y., Hirata K., Kawashima S., Hayashi Y., Itoh H., Yodoi J., and Yokoyama M. Expression of glutaredoxin in human coronary arteries: its potential role in antioxidant protection against atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1483-1487
26. Shioji K., Kishimoto C., Nakamura H., Masutani H., Yuan Z., Oka S., and Yodoi J. Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation 106 (2002) 1403-1409
27. Saitoh M., Nishitoh H., Fujii M., Takeda K., Tobiume K., Sawada Y., Kawabata M., Miyazono K., and Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 17 (1998) 2596-2606
28. Musi N., Hirshman M.F., Nygren J., Svanfeldt M., Bavenholm P., Rooyackers O., Zhou G., Williamson J.M., Ljunqvist O., Efendic S., Moller D.E., Thorell A., and Goodyear L.J. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51 (2002) 2074-2081
29. Zhang M., Dong Y., Xu J., Xie Z., Wu Y., Song P., Guzman M., Wu J., and Zou M.H. Thromboxane receptor activates the AMP-activated protein kinase in vascular smooth muscle cells via hydrogen peroxide. Circ. Res. 102 (2008) 328-337
30. Kukidome D., Nishikawa T., Sonoda K., Imoto K., Fujisawa K., Yano M., Motoshima H., Taguchi T., Matsumura T., and Araki E. Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes 55 (2006) 120-127
31. Ouedraogo R., Wu X., Xu S.Q., Fuchsel L., Motoshima H., Mahadev K., Hough K., Scalia R., and Goldstein B.J. Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. Diabetes 55 (2006) 1840-1846
32. Ceolotto G., Gallo A., Papparella I., Franco L., Murphy E., Iori E., Pagnin E., Fadini G.P., Albiero M., Semplicini A., and Avogaro A. Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 2627-2633
33. Brunet A., Sweeney L.B., Sturgill J.F., Chua K.F., Greer P.L., Lin Y., Tran H., Ross S.E., Mostoslavsky R., Cohen H.Y., Hu L.S., Cheng H.L., Jedrychowski M.P., Gygi S.P., Sinclair D.A., Alt F.W., and Greenberg M.E. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303 (2004) 2011-2015
34. van der Horst A., de Vries-Smits A.M., Brenkman A.B., van Triest M.H., van den Broek N., Colland F., Maurice M.M., and Burgering B.M. FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP. Nat. Cell Biol. 8 (2006) 1064-1073
35. Almeida M., Han L., Martin-Millan M., O'Brien C.A., and Manolagas S.C. Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription. J. Biol. Chem. 282 (2007) 27298-27305
36. Owusu-Ansah E., Yavari A., Mandal S., and Banerjee U. Distinct mitochondrial retrograde signals control the G1-S cell cycle checkpoint. Nat. Genet. 40 (2008) 356-361
37. Nakamura T., and Sakamoto K. Forkhead transcription factor FOXO subfamily is essential for reactive oxygen species-induced apoptosis. Mol. Cell. Endocrinol. 281 (2008) 47-55
38. Kops G.J., Dansen T.B., Polderman P.E., Saarloos I., Wirtz K.W., Coffer P.J., Huang T.T., Bos J.L., Medema R.H., and Burgering B.M. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 419 (2002) 316-321
39. Tothova Z., Kollipara R., Huntly B.J., Lee B.H., Castrillon D.H., Cullen D.E., McDowell E.P., Lazo-Kallanian S., Williams I.R., Sears C., Armstrong S.A., Passegue E., DePinho R.A., and Gilliland D.G. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 128 (2007) 325-339
40. Marinkovic D., Zhang X., Yalcin S., Luciano J.P., Brugnara C., Huber T., and Ghaffari S. Foxo3 is required for the regulation of oxidative stress in erythropoiesis. J. Clin. Invest. 117 (2007) 2133-2144
41. Hattangadi S.M., and Lodish H.F. Regulation of erythrocyte lifespan: do reactive oxygen species set the clock?. J. Clin. Invest. 117 (2007) 2075-2077
42. Arden K.C. FoxOs in tumor suppression and stem cell maintenance. Cell 128 (2007) 235-237
43. Zheng X., Yang Z., Yue Z., Alvarez J.D., and Sehgal A. FOXO and insulin signaling regulate sensitivity of the circadian clock to oxidative stress. Proc. Natl. Acad. Sci. USA 104 (2007) 15899-15904